Watch Ticker

Sagimet Biosciences Inc. Series A Common Stock

Go to Sagimet Biosciences Inc. Series A Common Stock Website

$8.97

0.52 (6.15%)

Live

Previous Close

$8.45

Day Range

$8.37 - $9.3752

Previous Day Range

$8.27 - $8.69

Market Cap

$265.6 million USD

Day Vol.

598140

Previous Day Vol.

584468

Currency

USD

Primary Exchange

None

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolis...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Sagimet Biosciences - Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Sagimet Biosciences will participate in the Canaccord Genuity Growth Conference and has completed a successful Phase 2b clinical trial for denifanstat in treating metabolic dysfunction associated steatohepatitis (MASH). The company has also initiated a Phase 1 trial for a new FASN inhibitor targeting acne treatment.

Related tickers: SGMT.

Read Full Article

N/A - Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Sagimet Biosciences announced positive Phase 3 results for its acne drug denifanstat, which met all primary and secondary endpoints versus placebo and was well-tolerated. The company also discussed plans for a first-in-human study of a second oral FASN inhibitor drug candidate, TVB-3567, for acne.

Related tickers: SGMT.

Read Full Article

Trending Tickers

Please sign in to view